#ESMO26|#VOLGA
⭐️PhIII:PeriOp Durva ± Treme + NeoAdj EV vs control in cis-ineligible/refusing MIBC
•Durva+EV: 2-yr EFS 64% vs 45% (HR 0.51); 2-yr OS 78% vs 69% (HR 0.58)
•pCR 45% vs 10%
•G3/4 TRAEs 30% (D+EV) vs 42% (+Treme)
#BladderCancer #MIBC #bcsm #OncTwitter @tompowles1
9 浏览 · 0 赞 · 0 转发 · 0 回复
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org来源：OncUpdates · x.com